Skip to content

NT-ProBNP as a Predictive Biomarker for Cardiac and Neurodevelopmental Outcomes in Preterm Infants

NT-ProBNP as a Predictive Biomarker for Cardiac and Neurodevelopmental Outcomes in Preterm Infants

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00037723
Enrollment
200
Registered
2025-08-27
Start date
2025-09-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm

Interventions

Group 1: Very preterm infants with a birth weight < 1500 g, with at least one NT-proBNP measurement and available cardiac or deurodevelopmental follow-up at 2 years corrected age.

Sponsors

KUNO Klinik St. Hedwig Barmherzige Brüder Regensburg
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: < 1500 g at birth at least one measurement of NT-proBNP and had either a cardiac follow up or neurodevelopmental follow up at 2 year corrected age.

Exclusion criteria

Exclusion criteria: > 1500 g at birth

Design outcomes

Primary

MeasureTime frame
- Neurological development at corrected age of 2 years (Bayley-III) - Cardiac outcome at follow-up: systolic and diastolic function, residual PDA, signs of pulmonary hypertension.

Secondary

MeasureTime frame
Correlations between NT-proBNP levels and echocardiographic and clinical parameters. Associations between NT-proBNP levels and neonatal complications (BPD, IVH, NEC, sepsis and ROP). Analysis of the predictive value of NT-proBNP for subsequent neurological development and cardiac outcomes.

Countries

Germany

Contacts

Public ContactSven Wellmann

KUNO Klinik St. Hedwig Barmherzige Brüder Regensburg

neonatologie@barmherzige-regensburg.de+49 941 369-5401

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026